The Promise and Challenge of Therapeutic MicroRNA Silencing in Diabetes and Metabolic Diseases.
MicroRNAs (miRNAs) are small, non-coding, RNA molecules that regulate gene expression. They have a long evolutionary history and are found in plants, viruses, and animals. Although initially discovered in 1993 in Caenorhabditis elegans, they were not appreciated as widespread and abundant gene regulators until the early 2000s. Studies in the last decade have found that miRNAs confer phenotypic robustness in the face of environmental perturbation, may serve as diagnostic and prognostic indicators of disease, underlie the pathobiology of a wide array of complex disorders, and represent compelling therapeutic targets. Pre-clinical studies in animal models have demonstrated that pharmacologic manipulation of miRNAs, mostly in the liver, can modulate metabolic phenotypes and even reverse the course of insulin resistance and diabetes. There is cautious optimism in the field about miRNA-based therapies for diabetes, several of which are already in various stages of clinical trials. This review will highlight both the promise and the most pressing challenges of therapeutic miRNA silencing in diabetes and related conditions.
Department of Genetics, School of Medicine, UNC Chapel Hill, Chapel Hill, NC, 27599, USA. praveen_sethupathy@med.unc.edu.|Lineberger Comprehensive Cancer Center, School of Medicine, UNC Chapel Hill, Chapel Hill, NC, 27599, USA. praveen_sethupathy@med.unc.edu.
Praveen
P
Sethupathy
D000818:Animals; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000235:genetics* / Q000628:therapy; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000235:genetics; D007333:Insulin Resistance; D024821:Metabolic Syndrome / Q000235:genetics* / Q000628:therapy; D035683:MicroRNAs / Q000235:genetics*; D009765:Obesity / Q000150:complications / Q000235:genetics
D035683:MicroRNAs
Anti-sense oligonucleotide; Aptamer; Diabetes; Metabolic disease; MicroRNA; Therapeutics